Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $122 to $119.
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $122 to $119.